ADMS - Adamas Pharmaceuticals, Inc.
| Previous Close | 6.00 |
| Open | 6.02 |
| Bid | 0.00 x 800 |
| Ask | 8.50 x 800 |
| Day's Range | 5.94 - 6.12 |
| 52 Week Range | 4.20 - 29.49 |
| Volume | 158,114 |
| Avg. Volume | 362,041 |
| Market Cap | 165.199M |
| Beta (3Y Monthly) | 2.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.61 |
| Earnings Date | Aug 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.75 |
- GlobeNewswire•13 hours ago
Adamas to Announce Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
EMERYVILLE, Calif., July 23, 2019 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 second quarter financial results on Thursday,.
- GlobeNewswire•16 days ago
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 11,000 shares of the company’s common stock, at a per share exercise price of $5.82, the closing trading price on July 8, 2019, and restricted stock units to acquire 5,500 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- Zacks•16 days ago
Top Ranked Momentum Stocks to Buy for July 8th
Top Ranked Momentum Stocks to Buy for July 8th
- Zacks•19 days ago
Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.
- Insider Monkey•25 days ago
Hedge Funds Are Dumping Adamas Pharmaceuticals Inc (ADMS)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the […]
- ACCESSWIRE•26 days ago
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 28, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- PR Newswire•27 days ago
Lifshitz & Miller LLP Announces Investigation of Adamas Pharmaceuticals, Inc., ASGN Incorporated, Box, Inc., ChinaCache International Holdings Ltd, Mammoth Energy Services, Inc., Realogy Holdings Corp., Total System Services, Inc., and Verint Systems Inc.
NEW YORK , June 27, 2019 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (ADMS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Adamas ...
- ACCESSWIRE•28 days ago
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- Zacks•29 days ago
Will Adamas Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor Adamas Pharmaceuticals.
- Zacks•last month
Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%
Bausch Health (BHC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Simply Wall St.•last month
Should You Worry About Adamas Pharmaceuticals, Inc.'s (NASDAQ:ADMS) CEO Salary Level?
In 2000 Gregory Went was appointed CEO of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). This analysis aims first to...
- Zacks•last month
Allergan (AGN) in Focus: Stock Moves 6.2% Higher
Allergan (AGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Benzinga•last month
The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals ...
- GlobeNewswire•last month
Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinson’s Disease
Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced a retrospective data analysis from pooled Phase 3 trials of GOCOVRI® (amantadine) extended release capsules were presented at the International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, and published in the Journal of Parkinson’s Disease, online 8th May 2019.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ADMS earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Adamas Pharmaceuticals Inc Earnings Call
- Zacks•last month
What Makes Adamas (ADMS) a New Buy Stock
Adamas (ADMS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Business Wire•last month
ADMS INVESTORS NOTICE: Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc.
The law firm of Lieff Cabraser Heimann & Bernstein, LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (ADMS), including investors who purchased Adamas common stock directly in the Company’s January 24, 2018 secondary public offering (“SPO”). Adamas investors who wish to learn more about the investigation should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.
- GlobeNewswire•last month
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.
NEW YORK, June 17, 2019 -- Levi & Korsinsky reminds investors that it has commenced an investigation of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQGM:.
- ACCESSWIRE•last month
INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 12, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- GlobeNewswire•last month
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (ADMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. In January 2018, Adamas completed a secondary public offering (“SPO”), issuing approximately 3 million shares of common stock priced at $41.50 per share. In October 2018, Merrill Lynch released a study which cast serious doubt on the ability of Gocovri, Adamas’s treatment for dyskinesia in Parkinson’s disease patients treated with levodopa therapy, to achieve a sizeable market share and emphasized that Adamas had failed to include critical information. In March 2019, Adamas backtracked on prior issued growth estimates and no longer made predictions regarding Gocovri’s ability to achieve a sizeable market share. Adamas’s stock price has fallen sharply since the SPO and now trades well below the offering price.
- ACCESSWIRE•last month
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 11, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, ...
- ACCESSWIRE•last month
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 10, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, ...
- Business Wire•last month
ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (ADMS) directly in the Company’s January 24, 2018 secondary public offering (“SPO”). If you purchased Adamas common stock directly in the SPO, you may move the Court for appointment as lead plaintiff.
